These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

403 related articles for article (PubMed ID: 12126149)

  • 1. Expression and significance of p53, rb, p21/waf-1, p16/ink-4a, and PTEN tumor suppressors in canine melanoma.
    Koenig A; Bianco SR; Fosmire S; Wojcieszyn J; Modiano JF
    Vet Pathol; 2002 Jul; 39(4):458-72. PubMed ID: 12126149
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tumor suppressor PTEN is mutated in canine osteosarcoma cell lines and tumors.
    Levine RA; Forest T; Smith C
    Vet Pathol; 2002 May; 39(3):372-8. PubMed ID: 12014501
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Functional loss of p21/Waf-1 in a case of benign canine multicentric melanoma.
    Ritt MG; Wojcieszyn J; Modiano JF
    Vet Pathol; 1998 Mar; 35(2):94-101. PubMed ID: 9539362
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of human tissue to assess the oncogenic activity of melanoma-associated mutations.
    Chudnovsky Y; Adams AE; Robbins PB; Lin Q; Khavari PA
    Nat Genet; 2005 Jul; 37(7):745-9. PubMed ID: 15951821
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunohistochemical detection of p53, PTEN, Rb, and p16 in canine osteosarcoma using tissue microarray.
    Russell DS; Jaworski L; Kisseberth WC
    J Vet Diagn Invest; 2018 Jul; 30(4):504-509. PubMed ID: 29629647
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inactivation of p53 and retinoblastoma family pathways in canine osteosarcoma cell lines.
    Levine RA; Fleischli MA
    Vet Pathol; 2000 Jan; 37(1):54-61. PubMed ID: 10643981
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dysregulation of the Wnt/beta-catenin signaling pathway in canine cutaneous melanotic tumor.
    Han JI; Kim DY; Na KJ
    Vet Pathol; 2010 Mar; 47(2):285-91. PubMed ID: 20139375
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The significance of p53 and retinoblastoma pathways in canine hemangiosarcoma.
    Yonemaru K; Sakai H; Murakami M; Kodama A; Mori T; Yanai T; Maruo K; Masegi T
    J Vet Med Sci; 2007 Mar; 69(3):271-8. PubMed ID: 17409643
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunohistochemical and molecular analysis of p53, RB, and PTEN in malignant peripheral nerve sheath tumors.
    Mawrin C; Kirches E; Boltze C; Dietzmann K; Roessner A; Schneider-Stock R
    Virchows Arch; 2002 Jun; 440(6):610-5. PubMed ID: 12070601
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relative reciprocity of NRAS and PTEN/MMAC1 alterations in cutaneous melanoma cell lines.
    Tsao H; Zhang X; Fowlkes K; Haluska FG
    Cancer Res; 2000 Apr; 60(7):1800-4. PubMed ID: 10766161
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Frequent genetic defects in the p16/INK4A tumor suppressor in canine cell models of breast cancer and melanoma.
    Lutful Kabir FM; DeInnocentes P; Bird AC; Bird RC
    In Vitro Cell Dev Biol Anim; 2021 May; 57(5):519-530. PubMed ID: 34014456
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differential expression of the cyclin-dependent kinase inhibitors p16 and p21 in the human melanocytic system.
    Wang Y; Becker D
    Oncogene; 1996 Mar; 12(5):1069-75. PubMed ID: 8649798
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recurrent patterns of dual RB and p53 pathway inactivation in melanoma.
    Yang G; Rajadurai A; Tsao H
    J Invest Dermatol; 2005 Dec; 125(6):1242-51. PubMed ID: 16354195
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dual inactivation of RB and p53 pathways in RAS-induced melanomas.
    Bardeesy N; Bastian BC; Hezel A; Pinkel D; DePinho RA; Chin L
    Mol Cell Biol; 2001 Mar; 21(6):2144-53. PubMed ID: 11238948
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Canine gastric carcinoma: immunohistochemical expression of cell cycle proteins (p53, p21, and p16) and heat shock proteins (Hsp27 and Hsp70).
    Carrasco V; Canfrán S; Rodríguez-Franco F; Benito A; Sáinz A; Rodríguez-Bertos A
    Vet Pathol; 2011 Jan; 48(1):322-9. PubMed ID: 20587688
    [TBL] [Abstract][Full Text] [Related]  

  • 16. TabBO: a model reflecting common molecular features of androgen-independent prostate cancer.
    Navone NM; Rodriquez-Vargas MC; Benedict WF; Troncoso P; McDonnell TJ; Zhou JH; Luthra R; Logothetis CJ
    Clin Cancer Res; 2000 Mar; 6(3):1190-7. PubMed ID: 10741751
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Frequent co-alterations of TP53, p16/CDKN2A, p14ARF, PTEN tumor suppressor genes in human glioma cell lines.
    Ishii N; Maier D; Merlo A; Tada M; Sawamura Y; Diserens AC; Van Meir EG
    Brain Pathol; 1999 Jul; 9(3):469-79. PubMed ID: 10416987
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Epigenetic PTEN silencing in malignant melanomas without PTEN mutation.
    Zhou XP; Gimm O; Hampel H; Niemann T; Walker MJ; Eng C
    Am J Pathol; 2000 Oct; 157(4):1123-8. PubMed ID: 11021816
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression of the tumor suppressor genes NF2, 4.1B, and TSLC1 in canine meningiomas.
    Dickinson PJ; Surace EI; Cambell M; Higgins RJ; Leutenegger CM; Bollen AW; LeCouteur RA; Gutmann DH
    Vet Pathol; 2009 Sep; 46(5):884-92. PubMed ID: 19429976
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular pathology of primary and metastatic ductal pancreatic lesions: analyses of mutations and expression of the p53, mdm-2, and p21/WAF-1 genes in sporadic and familial lesions.
    Ruggeri BA; Huang L; Berger D; Chang H; Klein-Szanto AJ; Goodrow T; Wood M; Obara T; Heath CW; Lynch H
    Cancer; 1997 Feb; 79(4):700-16. PubMed ID: 9024708
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.